Porownywarka

Ovagen vs Livagen side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

OvagenLivagen

Udostępnij porównanie peptydów

Wlasciwosc	Ovagen	Livagen
Kategoria	Bioregulatory	Bioregulatory
Znany tez jako	Glu-Asp-Leu, EDL	Lys-Glu-Asp-Ala, KEDA
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Preclinical research; reportedly approved in Russia as a supplement Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Preclinical research; reported as approved in Russia as a supplement Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Liver support, GI health, detoxification	Gene expression, cellular aging, liver health
Jak dziala	Ovagen is proposed to fit the peptide bioregulator model: a very short peptide, EDL, may be transported into cells and then affect gene transcription in a tissue-selective way. The source frames liver cells and gastrointestinal epithelium as claimed target tissues. It also cautions that this is an extrapolated hypothesis rather than a mechanism proven directly for Ovagen in independent studies.	Livagen is presented as a short peptide bioregulator with a proposed epigenetic mode of action. The supplied source describes in vitro findings in which KEDA was associated with less condensed pericentromeric heterochromatin and increased ribosomal gene activity in cells from older donors. This remains a hypothesis based on cell-level work; the source does not establish how a tetrapeptide would produce selective nuclear effects in humans.
Typowe dawkowanie	10-20 mg daily · Once or twice daily	10-20 mg daily · Once or twice daily · 10-30 day cycles · Oral capsules or sublingual
Dawkowanie z badań	10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual	10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual
Typowy czas trwania	10-30 day cycles	10-30 day cycles
Podanie	Oral capsules or sublingual	Oral capsules or sublingual
Timing	Morning on an empty stomach Take on an empty stomach	Morning on an empty stomach Take on an empty stomach
Poziom dowodów	Przedkliniczne	Przedkliniczne
Mozliwe skutki uboczne	Generally well-tolerated (Source reports this generally, but does not provide controlled safety data.) Limited safety data outside Russia (The evidence base described by the source is geographically and scientifically limited.) Not FDA approved (Regulatory status is a safety-context note, not an adverse effect.)	Generally reported as well tolerated (Source-reported safety characterization; detailed adverse event data are not provided.) Limited safety data outside Russia (Safety evidence is described as geographically and evidentially limited.) Not FDA approved (This is regulatory status, not an adverse effect.)
Podsumowanie researchu	The supplied evidence places Ovagen within the broader Khavinson peptide bioregulator category, where some publications discuss gene-expression or chromatin-related effects for other short peptides. For Ovagen or EDL specifically, the source describes the research base as thin, with claims about liver fibrosis or gut mucosa protection attributed mainly to marketing rather than controlled experiments. No registered human clinical trials or high-quality human efficacy evidence are identified in the supplied material.	The supplied research description centers on a narrow body of mechanistic work attributed mainly to Khavinson, Lezhava, and collaborators. It highlights a 2002 Bulletin of Experimental Biology and Medicine report in which cultured lymphocytes from older donors were exposed to Livagen and assessed for ribosomal gene activity and heterochromatin structure. Related peptide bioregulators were reported in the same research line. The evidence described is cell-level and mechanistic rather than clinical, and the source states that randomized human trials for Livagen were not identified.
Referencje	Peptibase peptides Peptibase peptides +2 więcej Peptibase peptides Peptibase peptides	Źródło Źródło +2 więcej Źródło Źródło
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Ovagen

Livagen

Kategoria

Bioregulatory

Znany tez jako

Glu-Asp-Leu, EDL

Lys-Glu-Asp-Ala, KEDA

Zatwierdzony przez FDA

Nie

Status kliniczny

Preclinical research; reportedly approved in Russia as a supplement

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Preclinical research; reported as approved in Russia as a supplement

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Liver support, GI health, detoxification

Gene expression, cellular aging, liver health

Jak dziala

Ovagen is proposed to fit the peptide bioregulator model: a very short peptide, EDL, may be transported into cells and then affect gene transcription in a tissue-selective way. The source frames liver cells and gastrointestinal epithelium as claimed target tissues. It also cautions that this is an extrapolated hypothesis rather than a mechanism proven directly for Ovagen in independent studies.

Livagen is presented as a short peptide bioregulator with a proposed epigenetic mode of action. The supplied source describes in vitro findings in which KEDA was associated with less condensed pericentromeric heterochromatin and increased ribosomal gene activity in cells from older donors. This remains a hypothesis based on cell-level work; the source does not establish how a tetrapeptide would produce selective nuclear effects in humans.

Typowe dawkowanie

10-20 mg daily · Once or twice daily

10-20 mg daily · Once or twice daily · 10-30 day cycles · Oral capsules or sublingual

Dawkowanie z badań

10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual

Typowy czas trwania

10-30 day cycles

Podanie

Oral capsules or sublingual

Timing

Morning on an empty stomach

Take on an empty stomach

Morning on an empty stomach

Take on an empty stomach

Poziom dowodów

Przedkliniczne

Mozliwe skutki uboczne

Generally well-tolerated (Source reports this generally, but does not provide controlled safety data.)
Limited safety data outside Russia (The evidence base described by the source is geographically and scientifically limited.)
Not FDA approved (Regulatory status is a safety-context note, not an adverse effect.)

Generally reported as well tolerated (Source-reported safety characterization; detailed adverse event data are not provided.)
Limited safety data outside Russia (Safety evidence is described as geographically and evidentially limited.)
Not FDA approved (This is regulatory status, not an adverse effect.)

Podsumowanie researchu

The supplied evidence places Ovagen within the broader Khavinson peptide bioregulator category, where some publications discuss gene-expression or chromatin-related effects for other short peptides. For Ovagen or EDL specifically, the source describes the research base as thin, with claims about liver fibrosis or gut mucosa protection attributed mainly to marketing rather than controlled experiments. No registered human clinical trials or high-quality human efficacy evidence are identified in the supplied material.

The supplied research description centers on a narrow body of mechanistic work attributed mainly to Khavinson, Lezhava, and collaborators. It highlights a 2002 Bulletin of Experimental Biology and Medicine report in which cultured lymphocytes from older donors were exposed to Livagen and assessed for ribosomal gene activity and heterochromatin structure. Related peptide bioregulators were reported in the same research line. The evidence described is cell-level and mechanistic rather than clinical, and the source states that randomized human trials for Livagen were not identified.

Referencje

Peptibase peptides Peptibase peptides

+2 więcej

Peptibase peptides Peptibase peptides

Źródło Źródło

+2 więcej

Źródło Źródło

Pełny profil

Zobacz szczegóły